News & Events about Cytomx Therapeutics Inc.
-Achievement of clinical candidate is the first in the multi-target collaboration and triggersa $5 million milestone payment to CytomX- -CytomX-retained US co-commercialization and economic rights for select programs- SOUTH SAN FRANCISCO, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics...
Thinking about buying stock in Spruce Biosciences, CytomX Therapeutics, Boxed, Mobile Global Esports, or Emergent Biosolutions? Thinking about buying stock in Spruce Biosciences, CytomX Therapeutics, Boxed, Mobile Global Esports, or Emergent Biosolutions? PR Newswire NEW YORK, Jan. 6, 2023 NEW...
Thinking about buying stock in CytomX Therapeutics, Nio, Grab, Unity Software, or Sea? Thinking about buying stock in CytomX Therapeutics, Nio, Grab, Unity Software, or Sea? PR Newswire NEW YORK, Nov. 17, 2022 NEW YORK, Nov. 17, 2022 /PRNewswire/ -- InvestorsObserverissues critical PriceWatch...
Thinking about buying stock in iSpecimen, Leslie's, Las Vegas Sands, Atlas Corp, or CytomX Therapeutics? Thinking about buying stock in iSpecimen, Leslie's, Las Vegas Sands, Atlas Corp, or CytomX Therapeutics? PR Newswire NEW YORK, Sept. 26, 2022 NEW YORK, Sept. 26, 2022 /PRNewswire...
Ticker Report
7 months ago
HC Wainwright cut shares of CytomX Therapeutics (NASDAQ:CTMX Get Rating) from a buy rating to a neutral rating in a report published on Monday, The Fly reports. Several other research firms have also weighed in on CTMX. Barclays decreased their target price on shares of CytomX Therapeutics ...